[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524494":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":39,"responsibleParty":55,"collaborators":58,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":10,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Liaoning Cancer Hospital & Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Huaier Granule",null,"The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.",[13],"Drug: Huaier granule",{"label":15,"type":10,"description":16,"interventionNames":17},"Control","The subjects received standard platinum dual-drug chemotherapy.",[18],"Other: Control",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Huaier granule","The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.The subjects took Huaier granules orally, one bag (10g) per time, three times a day. Until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or when the researcher determines that there is no further benefit, whichever occurs first. Please refer to the drug manual for specific usage. It is recommended that patients start taking Huaier granules 1-2 weeks after surgery.",[9],[26],"Z20000109（NMPA Approval Number）",{"type":6,"name":15,"description":28,"armGroupLabels":29,"otherNames":10},"The subjects received standard platinum dual drug chemotherapy.The subjects were treated with carboplatin injection (300mg\u002Fm2, intravenous injection, first day) combined with pemetrexed disodium (pathological type: adenocarcinoma, intravenous injection, 500mg\u002Fm2) or albumin bound paclitaxel (pathological type: squamous cell carcinoma, 260mg\u002Fm2, intravenous injection, first day) every three weeks, with a maximum of four cycles.",[15],[31],{"name":32,"affiliation":5,"role":33},"Hongxu Liu, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":32,"role":36,"phone":37,"phoneExt":10,"email":38},"CONTACT","+8618040097698","hxliu@cmu.edu.cn",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Shenyang","Liaoning","110801","China","CN",{"type":48,"coordinates":49},"Point",[50,51],123.43278,41.79222,{"lat":51,"lon":50},[54],{"name":32,"role":36,"phone":37,"phoneExt":10,"email":38},{"type":33,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Hongxu Liu","professor",[59,62],{"name":60,"class":61},"LinkDoc Technology (Beijing) Co. Ltd.","INDUSTRY",{"name":63,"class":6},"Huazhong University of Science and Technology","100524494","observation-on-the-therapeutic-effect-of-huaier-granules-in-the-adjuvant-treatment-of-non-small-cell-lung-cancer-after-radical-surgery-100524494",false,"NCT06109454","Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery","Observational Study on the Efficacy and Safety of Huaier Granules Compared With Platinum Containing Dual Drug Combination Chemotherapy in Adjuvant Therapy for Resectable Stage II-IIIA Non-small Cell Lung Cancer After Radical Surgery","Inclusion Criteria:\n\n* 18 years old ≤ age ≤ 75, regardless of gender.\n* Confirmed as non-small cell lung cancer by histopathology, with pathological staging of stage Ⅱ-ⅢA.\n* Received radical R0 resection of lung cancer within 2 months before enrollment, and did not receive any postoperative adjuvant therapy or preoperative neoadjuvant therapy.\n* ECOG（Eastern Cooperative Oncology Group）score:0-2.\n* The patient voluntarily participated in the study, agreed to cooperate with the researcher for data collection, and signed an informed consent form.\n\nExclusion Criteria:\n\n* Known to be allergic to the components of Huaier granules or avoid or use Huaier granules with caution (Huaier group).\n* Those who have difficulty swallowing, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding, perforation, and other causes of difficulty in taking oral medication.\n* Non-small cell lung cancer patients who plan to receive targeted therapy, immunotherapy, chemotherapy combined with immunotherapy, radiotherapy, synchronous radiotherapy and chemotherapy during the study period.\n* The patient has a history of other new malignant tumors within 5 years.\n* The expected survival time of the patient is less than half a year.\n* Surgical complications that have not recovered or are accompanied by severe infections after radical resection of lung cancer.\n* Pregnant or lactating women or planned pregnancy preparation.\n* The patient has received other traditional Chinese patent medicines and simple preparations with anti-tumor effect in the past one month (including but not limited to compound cantharidin capsule, cinobufagin capsule, Kangai injection, Brucea javanica injection, etc., the specific instructions shall prevail).\n* The patient suffers from severe mental illness or other reasons that the researcher deems unsuitable to participate in this study.","ALL","18 Years","75 Years",{"count":75,"type":76},240,"ESTIMATED","OBSERVATIONAL","This study is a multicenter, prospective, and observational clinical study aimed at exploring whether the 3-year DFS in the Huaier group is not inferior to the control group receiving standard platinum dual-drug chemotherapy.",[80],"Non-small Cell Lung Cancer",[22,80,82,83],"Efficacy","Safety","2024-05-08",{"date":86,"type":87},"2024-05-10","ACTUAL",{"date":89,"type":87},"2024-03-21",{"date":91,"type":76},"2028-10",{"name":5,"class":6},1]